Jamie Fowler
A5035818450- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Digital Mental Health Interventions
- Schizophrenia research and treatment
- Bacterial Infections and Vaccines
- Retinal and Optic Conditions
- Educational Assessment and Improvement
- Space Science and Extraterrestrial Life
- Aging, Elder Care, and Social Issues
- Heparin-Induced Thrombocytopenia and Thrombosis
- Virus-based gene therapy research
- Treatment of Major Depression
- Health Systems, Economic Evaluations, Quality of Life
- Immune responses and vaccinations
- Intergenerational Family Dynamics and Caregiving
- Mobile Health and mHealth Applications
- Stress Responses and Cortisol
- Tryptophan and brain disorders
- Bipolar Disorder and Treatment
- Intramuscular injections and effects
- COVID-19 and Mental Health
- Linguistics and language evolution
- Long-Term Effects of COVID-19
University of Oxford
2020-2024
Jenner Institute
2020-2023
Oxford BioMedica (United Kingdom)
2022
Churchill Hospital
2022
Otsuka (United States)
2019-2021
Curtin University
2021
The University of Texas Health Science Center at Houston
2019
Methodist Hospital
2019
Baylor College of Medicine
2017
SummaryBackgroundCOVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between first and second dose becomes longer. Conversely, with no constraints considering administering a third dose. We assessed persistence of immunogenicity after single ChAdOx1 nCoV-19 (AZD1222), an extended (44–45 weeks) dose, response to booster given 28–38 weeks dose.MethodsIn this substudy, volunteers aged 18–55 years who were enrolled phase 1/2...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity varies between individuals, and immune responses correlate with efficacy. Using data from 1,076 participants enrolled in ChAdOx1 nCov-19 efficacy trials the United Kingdom, we found that inter-individual variation normalized antibody against SARS-CoV-2 spike its receptor-binding domain (RBD) at 28 days after first vaccination shows genome-wide significant association major histocompatibility complex...
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy the phase II/III COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses ChAdOx1 nCoV-19 (AZD1222) 4–6 weeks apart and were followed for 6 months. Responses to determined by serology (IgG ELISA Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ...
BackgroundVaccination of children and young people against SARS-CoV-2 is recommended in some countries. Scarce data have been published on immune responses induced by COVID-19 vaccines younger than 18 years compared with the same that are available adults.MethodsCOV006 a phase 2, single-blind, randomised, controlled trial ChAdOx1 nCoV-19 (AZD1222) adolescents at four sites UK. Healthy participants aged 6–17 years, who did not history chronic respiratory conditions, laboratory-confirmed...
Abstract Background People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are few data longer term and the impact of a booster dose. Methods Adults HIV were enrolled into single arm open label study. Two doses ChAdOx1 nCoV-19 followed 12 months later by third heterologous vaccine Participants had undetectable...
Background: COVID-19 vaccine supply shortages are causing concerns about compromised immunity in some countries as the interval between first and second dose extends. Conversely, with no constraints considering administering a third dose. We assessed persistence of immunogenicity after single dose, an extended ChAdOx1 nCoV-19(AZD1222), response to late booster. Methods: Volunteers aged 18-55 years who were enrolled Phase 1/2 or 2/3 clinical trial nCoV-19 had received either two doses 5×10 10...
Abstract The trajectory of immune responses following the primary dose series determines decline in vaccine effectiveness over time. Here we report on maintenance during year a two-dose schedule ChAdOx1 nCoV-19/AZD1222, absence infection, and also explore decay antibody after infection. Total spike-specific IgG titres were lower with two low doses nCoV-19 vaccines (two doses) (P = 0.0006) than 2 standard (the approved dose) or followed by regimens. Longer intervals between first second...
Purpose: Symptoms of psychotic disorders can complicate efforts to accurately evaluate patients' medication ingestion. The digital medicine system (DMS), composed antipsychotic co-encapsulated with an ingestible sensor, wearable sensor patches, and a smartphone application, was developed objectively measure We assessed performance acceptance the DMS in subjects disorders. Methods: This 8-week open-label, single-arm, multicenter, Phase 4 pragmatic study (NCT 03568500; EudraCT...
In patients with schizophrenia, medication adherence is important for relapse prevention, and effective monitoring essential treatment planning. A digital medicine system (DMS) has been developed to objectively monitor patient support clinical decision making regarding choices. This study assesses the acceptance performance of DMS in adults schizoaffective disorder or first-episode psychosis healthcare professionals (HCPs).This a multicentre, 8-week, single-arm, open-label pragmatic trial...
Abstract Early in vivo dynamics of human immune-cell activation across regionally activated lymphoid tissue sites upon immunisation are poorly characterised ancestrally diverse individuals. Here, we profiled draining and non-draining axillary lymph nodes (dLNs ndLNs) by ultrasound-guided fine-needle aspiration (FNA) 13 Black Asian ancestry individuals, before 3-7 days after vaccination with adjuvanted influenza vaccine. Draining but not ndLNs rapidly increased size post-vaccination, day 3,...
This qualitative phenomenological study explored the experiences and needs of eight older male caregivers after their partner entered full-time residential aged care within past 36 months. Semi-structured interviews were conducted, thematically analyzed, member-checked for accuracy. transition was a time significant turmoil caregivers. Feelings grief, loss, guilt, regret experienced, intertwined with feelings relief reassurance that would be well cared facility. Following transition, also...
Background: The ChAdOx1 nCoV-19 (AZD1222) vaccine is immunogenic and protects against COVID-19. However, data on immunogenicity are needed for the 40 million people living with HIV (PWH), who may have less functional immunity more associated co-morbidities than general population. Methods: Between 5th 24th November 2020, 54 adults HIV, aged 18-55 years, were enrolled into a single arm open label vaccination study within protocol of larger phase 2/3 COV002 trial. A prime-boost regimen...
Abstract Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study the phase 2/3 COV002 trial ( NCT04400838 ), 54 positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to determined by serology (IgG ELISA MesoScale Discovery (MSD)), neutralisation, ACE-2 inhibition,...
<strong>Objective:</strong> Adding to existing challenges in conducting clinical trials, COVID-19 has indefinitely affected modern research. Decentralized using telemedicine and digital technology, may prove critical the future of development. This type methodology psychiatric trials remains largely unexplored; therefore, we evaluated feasibility quality data collection a randomized, sham-interventional trial fully decentralized subjects with major depressive disorder (MDD)....